Identification of FISH biomarkers to detect chromosome abnormalities associated with prostate adenocarcinoma in tumour and field effect environment

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Zhang, Ying ^a   Perez, Thomas ^a   Blondin, Beth ^a   Du, Jing ^a   Liu, Ping ^a   Escarzaga, Diana ^b   Coon, John S ^b   Morrison, Larry E ^a   Pestova, Katerina ^a  

^a Abbott Molecular Inc   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Diagnosis; Field effect; Fish; Fluorescence in situ hybridisation; Genomic abnormalities; Prostate cancer

Indexed keywords

BIOLOGICAL MARKER; TUMOR MARKER;

ANEUPLOIDY; ARTICLE; CENTROMERE ENUMERATOR PROBE 10; CENTROMERE ENUMERATOR PROBE 7; CENTROMERE ENUMERATOR PROBE 8; CHROMOSOME 7; CHROMOSOME ABERRATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA PROBE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE DOSAGE; GENE LOSS; GENE PROBE; GENE REARRANGEMENT; HISTOLOGY; HUMAN; HUMAN TISSUE; LPL GENE; MALE; ONCOGENE MYC; PROSTATE ADENOCARCINOMA; PTEN GENE; SENSITIVITY AND SPECIFICITY; TMPRSS2 GENE; ADENOCARCINOMA; BIOPSY; GENETICS; PATHOLOGY; PROSTATECTOMY; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; RECEIVER OPERATING CHARACTERISTIC;

ADENOCARCINOMA; BIOPSY; CHROMOSOME ABERRATIONS; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; PROSTATECTOMY; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; ROC CURVE; TUMOR MARKERS, BIOLOGICAL;

EID: 84898597865     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-129     Document Type: Article

References (29)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics. CA Cancer J Clin 2012, 62:10-29. 10.3322/caac.20138, 22237781.
2. Shariat SF, Roehrborn CG. Using biopsy to detect prostate cancer. Rev Urol 2008, 10(4):262-280. 2615104, 19145270.
3. Nonn L, Ananthanarayanan V, Gann PH. Evidence for field cancerization of the prostate. Prostate 2009, 69:1470-1479. 10.1002/pros.20983, 3690597, 19462462.
4. Campos-Fernandes JL, Bastien L, Nicolaiew N, Robert G, Terry S, Vacherot F, Salomon L, Allory Y, Vordos D, Hoznek A, Yiou R, Patard JJ, Abbou CC, de la Taille A. Prostate cancer detection rate in patients with repeated extended 21-sample needle biopsy. Eur Urol 2009, 55:600-609. 10.1016/j.eururo.2008.06.043, 18597923.
5. Boccon-Gibod LM, Dumonceau O, Toublanc M, Ravery V, Boccon-Gibod LA. Micro-focal prostate cancer: a comparison of biopsy and radical prostatectomy specimen features. Eur Urol 2005, 48:895-899. 10.1016/j.eururo.2005.04.033, 16125298.
6. Arora R, Koch MO, Eble JN, Ulbright TM, Li L, Cheng L. Heterogeneity of gleason grade in multifocal adenocarcinoma of the prostate. Cancer 2004, 100:2362-2366. 10.1002/cncr.20243, 15160339.
7. Qian J, Wollan P, Bostwick DG. The extent and multicentricity of High-grade prostatic intraepithelial neoplasia in clinically localized prostate adenocarcinoma. Hum Pathol 1997, 28:143-148. 10.1016/S0046-8177(97)90097-6, 9023393.
8. de la Taille A, Antiphon P, Salomon L, Cherfan M, Porcher R, Hoznek A, Saint F, Vordos D, Cicco A, Yiou R, Zafrani ES, Chopin D, Abbou CC. Prospective evaluation of a 21-sample needle biopsy procedure designed to improve the prostate cancer detection rate. Urology 2003, 61(6):1181-1186. 10.1016/S0090-4295(03)00108-0, 12809894.
9. Mohler J, Bahnson RR, Boston B, Busby JE, D'Amico A, Eastham JA, Enke CA, George D, Horwitz EM, Huben RP, Kantoff P, Kawachi M, Kuettel M, Lange PH, Macvicar G, Plimack ER, Pow-Sang JM, Roach M, Rohren E, Roth BJ, Shrieve DC, Smith MR, Srinivas S, Twardowski P, Walsh PC. NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw 2010, 8:162-200.
10. Slaughter DP, Southwick HW, Smejkal W. Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer 1953, 6:963-968. 10.1002/1097-0142(195309)6:5<963::AID-CNCR2820060515>3.0.CO;2-Q, 13094644.
11. Höckel M, Dornhöfer N. The hydra phenomenon of cancer: why tumors recur locally after microscopically complete resection. Canc Res 2005, 65(8):2997-3002.
12. Chai H, Brown RE. Review: field effect in cancer-an update. Ann Clin Lab Sci 2009, 39(4):331-337.
13. Risk MC, Knudsen BS, Coleman I, Dumpit RF, Kristal AR, LeMeur N, Gentleman RC, True LD, Nelson PS, Lin DW. Differential gene expression in benign prostate epithelium of Men with and without prostate cancer: evidence for a prostate cancer field effect. Clin Canc Res 2010, 16:5414-5423.
14. Trujillo KA, Jones AC, Griffith JK, Bisoffi M. Markers of field cancerization: proposed clinical applications in prostate biopsies. Prostate Canc 2012, 2012:302894.
15. Haaland CM, Heaphy CM, Butler KS, Fischer EG, Griffith JK, Bisoffi M. Differential gene expression in tumoradjacent histologically normal prostatic tissue indicates field cancerisation. Int J Oncol 2009, 35:537-546.
16. Bishop R. Applications of fluorescence in situ hybridization (FISH) in detecting genetic aberrations of medical significance. Biosci Horiz 2010, 3(1):85-95.
17. Dellas A, Torhorst J, Jiang F, Proffitt J, Schultheiss E, Holzgreve W, Sauter G, Mihatsch MJ, Moch H. Prognostic value of genomic alterations in invasive cervical squamous cell carcinoma of clinical stage IB detected by comparative genomic hybridization. Canc Res 1999, 59(14):3475-3479.
18. Makarov DV, Loeb S, Getzenberg RH, Partin AW. Biomarkers for prostate cancer. Annu Rev Med 2009, 60:139-151. 10.1146/annurev.med.60.042307.110714, 18947298.
19. Nelson WG, De Marzo AM, Isaacs WB. Mechanisms of disease prostate cancer. N Engl J Med 2003, 349:366-381. 10.1056/NEJMra021562, 12878745.
20. Al-Maghrabi J, Vorobyova L, Toi A, Chapman W, Zielenska M, Squire JA. Identification of numerical chromosomal changes detected by interphase fluorescence in situ hybridization in high-grade prostate intraepithelial neoplasia as a predictor of carcinoma. Arch Pathol Lab Med 2002, 126(2):165-169.
21. Bova GS, Carter BS, Bussemakers MJ, Emi M, Fujiwara Y, Kyprianou N, Jacobs SC, Robinson JC, Epstein JI, Walsh PC, Isaacs WB. Homozygous deletion and frequent allelic loss of chromosome 8p22 loci in human prostate cancer. Cancer Res 1993, 53:3869-3873.
22. Yoshimoto M, Cunha IW, Coudry RA, Fonseca FP, Torres CH, Soares FA, Squire JA. FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome. Br J Cancer 2007, 97(5):678-685. Epub 2007 Aug 14, 10.1038/sj.bjc.6603924, 2360375, 17700571.
23. Metz CE. Receiver operating characteristic analysis: a tool for the quantitative evaluation of observer performance and imaging systems. J Am Coll Radiol 2006, 3:413-422. 10.1016/j.jacr.2006.02.021, 17412096.
24. Yanke BV, Gonen M, Scardino PT, Kattan MW. Validation of a nomogram for predicting positive repeat biopsy for prostate cancer. J Urol 2005, 173:421-424. 10.1097/01.ju.0000150522.82760.00, 15643192.
25. Mehrotra J, Varde S, Wang H, Chiu H, Vargo J, Gray K, Nagle RB, Neri JR, Mazumder A. Quantitative, spatial resolution of the epigenetic field effect in prostate cancer. Prostate 2008, 68(2):152-160. 10.1002/pros.20675, 18058812.
26. Joshua AM, Shen E, Yoshimoto M, Marrano P, Zielenska M, Evans AJ, Van der Kwast T, Squire JA. Topographical analysis of telomere length and correlation with genomic instability in whole mount prostatectomies. Prostate 2011, 71(7):778-790. 10.1002/pros.21294, 21031437.
27. Reguly B, Jakupciak JP, Parr RL. 3.4 kb mitochondrial genome deletion serves as a surrogate predictive biomarker for prostate cancer in histopathologically benign biopsy cores. J Canadian Urolog Assoc 2010, 4(5):E118-E122.
28. Mazzucchelli R, Barbisan F, Santinelli A, Lopez-Beltran A, Cheng L, Scarpelli M, Montironi R. Immunohistochemical expression of prostate tumor overexpressed 1 in cystoprostatectomies with incidental and insignificant prostate cancer. Further evidence for field effect in prostatic carcinogenesis. Hum Pathol 2011, 42(12):1931-1936. doi:10.1016/j.humpath.2011.02.014. Epub 2011 Jun 14, 10.1016/j.humpath.2011.02.014, 21676431.
29. Jones AC, Trujillo KA, Phillips GK, Fleet TM, Murton JK, Severns V, Shah SK, Davis MS, Smith AY, Griffith JK, Fischer EG, Bisoffi M. Early growth response 1 and fatty acid synthase expression is altered in tumor adjacent prostate tissue and indicates field cancerization. Prostate 2012, 72(11):1159-1170. doi:10.1002/pros.22465. Epub 2011 Nov 29, 10.1002/pros.22465, 3340489, 22127986.